Characterization of CD4 and CD8 T cell responses in MuSK myasthenia gravis

Journal of Autoimmunity

Volumn 52, Issue , 2014, Pages 130-138

  Yi, J S ^a   Guidon, A ^a   Sparks, S ^a   Osborne, R ^a   Juel, V C ^a   Massey, J M ^a   Sanders, D B ^a   Weinhold, K J ^a   Guptill, J T ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Autoimmunity; Human; MuSK protein; Myasthenia gravis; Regulatory; T lymphocytes

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 21; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA; AZATHIOPRINE; MUSK PROTEIN; MYCOPHENOLATE MOFETIL; PREDNISONE; PROTEIN; UNCLASSIFIED DRUG; CHOLINERGIC RECEPTOR; CYTOKINE; IMMUNOGLOBULIN G; MUSK PROTEIN, HUMAN; PROTEIN TYROSINE KINASE;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BLOOD SAMPLING; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; LYMPHOCYTE FUNCTION; MUSCLE SPECIFIC TYROSINE KINASE MYASTHENIA GRAVIS; MYASTHENIA GRAVIS; PHENOTYPE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; BLOOD; CORTICOSTEROID THERAPY; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; PLASMAPHERESIS; TH1 CELL; TH17 CELL; THYMECTOMY; CELL SEPARATION; IMMUNOLOGY; IMMUNOPHENOTYPING; METABOLISM; MIDDLE AGED; SEX DIFFERENCE; YOUNG ADULT;

ADULT; AGED; CD8-POSITIVE T-LYMPHOCYTES; CELL SEPARATION; CYTOKINES; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOGLOBULIN G; IMMUNOPHENOTYPING; MIDDLE AGED; MYASTHENIA GRAVIS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, CHOLINERGIC; SEX FACTORS; TH1 CELLS; TH17 CELLS; YOUNG ADULT;

EID: 84904314724     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2013.12.005     Document Type: Article

References (100)

1. Meriggioli M., Sanders D. Disorders of neuromuscular transmission. Neurology in clinical practice 2012, Heinemann Elsevier, Philadelphia: Butterworths. W.G. Bradley, R. D, G.M. Fenichel, J. Jancovic (Eds.).
2. Guptill J.T., Sanders D.B., Evoli A. Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts. Muscle Nerve 2011, 44:36-40.
3. Pasnoor M., Wolfe G.I., Nations S., Trivedi J., Barohn R.J., Herbelin L., et al. Clinical findings in MuSK-antibody positive myasthenia gravis: a U.S. experience. Muscle Nerve 2010, 41:370-374.
4. Leite M.I., Strobel P., Jones M., Micklem K., Moritz R., Gold R., et al. Fewer thymic changes in MuSK antibody-positive than in MuSK antibody-negative MG. Ann Neurol 2005, 57:444-448.
5. Lauriola L., Ranelletti F., Maggiano N., Guerriero M., Punzi C., Marsili F., et al. Thymus changes in anti-MuSK-positive and -negative myasthenia gravis. Neurology 2005, 64:536-538.
6. Stickler D.E., Massey J.M., Sanders D.B. MuSK-antibody positive myasthenia gravis: clinical and electrodiagnostic patterns. Clin Neurophysiol 2005, 116:2065-2068.
7. Scuderi F., Marino M., Colonna L., Mannella F., Evoli A., Provenzano C., et al. Anti-p110 autoantibodies identify a subtype of "seronegative" myasthenia gravis with prominent oculobulbar involvement. Lab Invest 2002, 82:1139-1146.
8. Hoch W., McConville J., Helms S., Newsom-Davis J., Melms A., Vincent A. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 2001, 7:365-368.
9. Cartaud A., Strochlic L., Guerra M., Blanchard B., Lambergeon M., Krejci E., et al. MuSK is required for anchoring acetylcholinesterase at the neuromuscular junction. JCell Biol 2004, 165:505-515.
10. Ghazanfari N., Fernandez K.J., Murata Y., Morsch M., Ngo S.T., Reddel S.W., et al. Muscle specific kinase: organiser of synaptic membrane domains. Int J Biochem Cell Biol 2011, 43:295-298.
11. Niks E.H., van Leeuwen Y., Leite M.I., Dekker F.W., Wintzen A.R., Wirtz P.W., et al. Clinical fluctuations in MuSK myasthenia gravis are related to antigen-specific IgG4 instead of IgG1. JNeuroimmunol 2008, 195:151-156.
12. Kawakami Y., Ito M., Hirayama M., Sahashi K., Ohkawara B., Masuda A., et al. Anti-MuSK autoantibodies block binding of collagen Q to MuSK. Neurology 2011, 77:1819-1826.
13. Cole R.N., Reddel S.W., Gervasio O.L., Phillips W.D. Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction. Ann Neurol 2008, 63:782-789.
14. Plomp J.J., Huijbers M.G., van der Maarel S.M., Verschuuren J.J. Pathogenic IgG4 subclass autoantibodies in MuSK myasthenia gravis. Ann N Y Acad Sci 2012, 1275:114-122.
15. Farrugia M.E., Bonifati D.M., Clover L., Cossins J., Beeson D., Vincent A. Effect of sera from AChR-antibody negative myasthenia gravis patients on AChR and MuSK in cell cultures. JNeuroimmunol 2007, 185:136-144.
16. Diaz-Manera J., Martinez-Hernandez E., Querol L., Klooster R., Rojas-Garcia R., Suarez-Calvet X., et al. Long-lasting treatment effect of rituximab in MuSK myasthenia. Neurology 2012, 78:189-193.
17. Illa I., Diaz-Manera J., Rojas-Garcia R., Pradas J., Rey A., Blesa R., et al. Sustained response to Rituximab in anti-AChR and anti-MuSK positive myasthenia gravis patients. JNeuroimmunol 2008, 201-202:90-94.
18. Jaretzki A., Barohn R.J., Ernstoff R.M., Kaminski H.J., Keesey J.C., Penn A.S., et al. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 2000, 55:16-23.
19. Sanders D.B., Tucker-Lipscomb B., Massey J.M. Asimple manual muscle test for myasthenia gravis: validation and comparison with the QMG score. Ann N Y Acad Sci 2003, 998:440-444.
20. Roederer M., Nozzi J.L., Nason M.C. SPICE: exploration and analysis of post-cytometric complex multivariate datasets. Cytometry A 2011, 79:167-174.
21. Oukka M. Th17 cells in immunity and autoimmunity. Ann Rheum Dis 2008, 67(Suppl.3):iii26-iii29.
22. Waite J.C., Skokos D. Th17 response and inflammatory autoimmune diseases. Int J Inflam 2012, 2012:819467.
23. Deaglio S., Dwyer K.M., Gao W., Friedman D., Usheva A., Erat A., et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. JExp Med 2007, 204:1257-1265.
24. Fletcher J.M., Lonergan R., Costelloe L., Kinsella K., Moran B., O'Farrelly C., et al. CD39+Foxp3+ regulatory T Cells suppress pathogenic Th17 cells and are impaired in multiple sclerosis. JImmunol 2009, 183:7602-7610.
25. Pantaleo G., Harari A. Functional signatures in antiviral T-cell immunity for monitoring virus-associated diseases. Nat Rev Immunol 2006, 6:417-423.
26. Gattinoni L., Klebanoff C.A., Restifo N.P. Paths to stemness: building the ultimate antitumour T cell. Nat Rev Cancer 2012, 12:671-684.
27. Boneva N., Frenkian-Cuvelier M., Bidault J., Brenner T., Berrih-Aknin S. Major pathogenic effects of anti-MuSK antibodies in myasthenia gravis. JNeuroimmunol 2006, 177:119-131.
28. McConville J., Farrugia M.E., Beeson D., Kishore U., Metcalfe R., Newsom-Davis J., et al. Detection and characterization of MuSK antibodies in seronegative myasthenia gravis. Ann Neurol 2004, 55:580-584.
29. Leite M.I., Jacob S., Viegas S., Cossins J., Clover L., Morgan B.P., et al. IgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis. Brain J Neurol 2008, 131:1940-1952.
30. Ohta K., Shigemoto K., Fujinami A., Maruyama N., Konishi T., Ohta M. Clinical and experimental features of MuSK antibody positive MG in Japan. Eur J Neurol 2007, 14:1029-1034.
31. Shiraishi H., Motomura M., Yoshimura T., Fukudome T., Fukuda T., Nakao Y., et al. Acetylcholine receptors loss and postsynaptic damage in MuSK antibody-positive myasthenia gravis. Ann Neurol 2005, 57:289-293.
32. Ahlberg R., Yi Q., Pirskanen R., Matell G., Swerup C., Rieber E.P., et al. Treatment of myasthenia gravis with anti-CD4 antibody: improvement correlates to decreased T-cell autoreactivity. Neurology 1994, 44:1732-1737.
33. Morgutti M., Conti-Tronconi B.M., Sghirlanzoni A., Clementi F. Cellular immune response to acetylcholine receptor in myasthenia gravis: II. Thymectomy and corticosteroids. Neurology 1979, 29:734-738.
34. Nath A., Kerman R.H., Novak I.S., Wolinsky J.S. Immune studies in human immunodeficiency virus infection with myasthenia gravis: a case report. Neurology 1990, 40:581-583.
35. Wang Z.Y., Karachunski P.I., Howard J.F., Conti-Fine B.M. Myasthenia in SCID mice grafted with myasthenic patient lymphocytes: role of CD4+ and CD8+ cells. Neurology 1999, 52:484-497.
36. Conti-Fine B.M., Milani M., Wang W. CD4+ T cells and cytokines in the pathogenesis of acquired myasthenia gravis. Ann N Y Acad Sci 2008, 1132:193-209.
37. Utsugisawa K., Nagane Y., Obara D., Kondoh R., Yonezawa H., Tohgi H. Interleukin-2 production by peripheral blood mononuclear cells from patients with myasthenia gravis. Eur Neurol 2003, 49:160-163.
38. Roche J.C., Capablo J.L., Larrad L., Gervas-Arruga J., Ara J.R., Sanchez A., et al. Increased serum interleukin-17 levels in patients with myasthenia gravis. Muscle Nerve 2011, 44:278-280.
39. Grob D., Brunner N., Namba T., Pagala M. Lifetime course of myasthenia gravis. Muscle Nerve 2008, 37:141-149.
40. Juel V.C., Massey J.M. Myasthenia gravis. Orphanet J Rare Dis 2007, 2:44.
41. Diaz-Manera J., Rojas Garcia R., Illa I. Treatment strategies for myasthenia gravis: an update. Expert Opin Pharmacother 1873-83, 13.
42. Pevzner A., Schoser B., Peters K., Cosma N.C., Karakatsani A., Schalke B., et al. Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis. JNeurol 2012, 259:427-435.
43. Higuchi O., Hamuro J., Motomura M., Yamanashi Y. Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis. Ann Neurol 2011, 69:418-422.
44. Janer M., Cowland A., Picard J., Campbell D., Pontarotti P., Newsom-Davis J., et al. Asusceptibility region for myasthenia gravis extending into the HLA-class I sector telomeric to HLA-C. Human Immunol 1999, 60:909-917.
45. Giraud M., Beaurain G., Yamamoto A.M., Eymard B., Tranchant C., Gajdos P., et al. Linkage of HLA to myasthenia gravis and genetic heterogeneity depending on anti-titin antibodies. Neurology 2001, 57:1555-1560.
46. Chen W.H., Chiu H.C., Hseih R.P. Association of HLA-Bw46DR9 combination with juvenile myasthenia gravis in Chinese. JNeurol Neurosurg Psychiatr 1993, 56:382-385.
47. Matsuki K., Juji T., Tokunaga K., Takamizawa M., Maeda H., Soda M., et al. HLA antigens in Japanese patients with myasthenia gravis. JClin Invest 1990, 86:392-399.
48. Giraud M., Vandiedonck C., Garchon H.J. Genetic factors in autoimmune myasthenia gravis. Ann N Y Acad Sci 2008, 1132:180-192.
49. Niks E.H., Kuks J.B., Roep B.O., Haasnoot G.W., Verduijn W., Ballieux B.E., et al. Strong association of MuSK antibody-positive myasthenia gravis and HLA-DR14-DQ5. Neurology 2006, 66:1772-1774.
50. Bartoccioni E., Scuderi F., Augugliaro A., Chiatamone Ranieri S., Sauchelli D., Alboino P., et al. HLA class II allele analysis in MuSK-positive myasthenia gravis suggests a role for DQ5. Neurology 2009, 72:195-197.
51. Wang Z.Y., Diethelm-Okita B., Okita D.K., Kaminski H.J., Howard J.F., Conti-Fine B.M. Tcell recognition of muscle acetylcholine receptor in ocular myasthenia gravis. JNeuroimmunol 2000, 108:29-39.
52. Wang Z.Y., Okita D.K., Howard J.F., Conti-Fine B.M. CD4+ T cell repertoire on the epsilon subunit of muscle acetylcholine receptor in myasthenia gravis. JNeuroimmunol 1998, 91:33-42.
53. Protti M.P., Manfredi A.A., Straub C., Howard J.F., Conti-Tronconi B.M. Immunodominant regions for T helper-cell sensitization on the human nicotinic receptor alpha subunit in myasthenia gravis. Proc Natl Acad Sci U S A 1990, 87:7792-7796.
54. Moiola L., Karachunski P., Protti M.P., Howard J.F., Conti-Tronconi B.M. Epitopes on the beta subunit of human muscle acetylcholine receptor recognized by CD4+ cells of myasthenia gravis patients and healthy subjects. JClin Invest 1994, 93:1020-1028.
55. Yi Q., Ahlberg R., Pirskanen R., Lefvert A.K. Acetylcholine receptor-reactive T cells in myasthenia gravis: evidence for the involvement of different subpopulations of T helper cells. JNeuroimmunol 1994, 50:177-186.
56. Levinson A.I., Zweiman B., Lisak R.P. Immunopathogenesis and treatment of myasthenia gravis. JClin Immunol 1987, 7:187-197.
57. Lisak R.P., Laramore C., Levinson A.I., Zweiman B., Moskovitz A.R. Suppressor T cells in myasthenia gravis and antibodies to acetylcholine receptor. Ann Neurol 1986, 19:87-89.
58. Levinson A.I., Dziarski A., Lisak R.P., Zweiman B., Moskovitz A.R., Brenner T., et al. Polyclonal B-cell activity in myasthenia gravis. Neurology 1981, 31:1198-1201.
59. Lisak R.P., Laramore C., Levinson A.I., Zweiman B., Moskovitz A.R., Witte A. Invitro synthesis of antibodies to acetylcholine receptor by peripheral bloodcells: role of suppressor T cells in normal subjects. Neurology 1984, 34:802-805.
60. Kohler S., Keil T.O., Swierzy M., Hoffmann S., Schaffert H., Ismail M., et al. Disturbed B cell subpopulations and increased plasma cells in myasthenia gravis patients. JNeuroimmunol 2013, 264:114-119.
61. Skeie GO, Apostolski S, Evoli A, Gilhus NE, Illa I, Harms L etal. Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol;17:893-902.
62. Matsui N., Nakane S., Saito F., Ohigashi I., Nakagawa Y., Kurobe H., et al. Undiminished regulatory T cells in the thymus of patients with myasthenia gravis. Neurology 2010, 74:816-820.
63. Xu W.H., Zhang A.M., Ren M.S., Zhang X.D., Wang F., Xu X.C., et al. Changes of Treg-associated molecules on CD4+CD25+Treg cells in myasthenia gravis and effects of immunosuppressants. JClin Immunol 2012, 32:975-983.
64. Thiruppathi M., Rowin J., Ganesh B., Sheng J.R., Prabhakar B.S., Meriggioli M.N. Impaired regulatory function in circulating CD4(+)CD25(high)CD127(low/-) T cells in patients with myasthenia gravis. Clin Immunol 2012, 145:209-223.
65. Fattorossi A., Battaglia A., Buzzonetti A., Ciaraffa F., Scambia G., Evoli A. Circulating and thymic CD4 CD25 T regulatory cells in myasthenia gravis: effect of immunosuppressive treatment. Immunology 2005, 116:134-141.
66. Battaglia A., Di Schino C., Fattorossi A., Scambia G., Evoli A. Circulating CD4+CD25+ T regulatory and natural killer T cells in patients with myasthenia gravis: a flow cytometry study. JBiol Regul Homeost Agents 2005, 19:54-62.
67. Li X., Xiao B.G., Xi J.Y., Lu C.Z., Lu J.H. Decrease of CD4(+)CD25(high)Foxp3(+) regulatory T cells and elevation of CD19(+)BAFF-R(+) B cells and soluble ICAM-1 in myasthenia gravis. Clin Immunol 2008, 126:180-188.
68. Masuda M., Matsumoto M., Tanaka S., Nakajima K., Yamada N., Ido N., et al. Clinical implication of peripheral CD4+CD25+ regulatory T cells and Th17 cells in myasthenia gravis patients. JNeuroimmunol 2010, 225:123-131.
69. Zhang Y., Wang H.B., Chi L.J., Wang W.Z. The role of FoxP3+CD4+CD25hi Tregs in the pathogenesis of myasthenia gravis. Immunol Lett 2009, 122:52-57.
70. Balandina A., Lecart S., Dartevelle P., Saoudi A., Berrih-Aknin S. Functional defect of regulatory CD4(+)CD25+ T cells in the thymus of patients with autoimmune myasthenia gravis. Blood 2005, 105:735-741.
71. Scarpino S., Di Napoli A., Stoppacciaro A., Antonelli M., Pilozzi E., Chiarle R., et al. Expression of autoimmune regulator gene (AIRE) and T regulatory cells in human thymomas. Clin Exp Immunol 2007, 149:504-512.
72. Strobel P., Rosenwald A., Beyersdorf N., Kerkau T., Elert O., Murumagi A., et al. Selective loss of regulatory T cells in thymomas. Ann Neurol 2004, 56:901-904.
73. Link J., Navikas V., Yu M., Fredrikson S., Osterman P.O., Link H. Augmented interferon-gamma, interleukin-4 and transforming growth factor-beta mRNA expression in blood mononuclear cells in myasthenia gravis. JNeuroimmunol 1994, 51:185-192.
74. Confalonieri P., Antozzi C., Cornelio F., Simoncini O., Mantegazza R. Immune activation in myasthenia gravis: soluble interleukin-2 receptor, interferon-gamma and tumor necrosis factor-alpha levels in patients' serum. JNeuroimmunol 1993, 48:33-36.
75. Hartung H.P., Reiners K., Schmidt B., Stoll G., Toyka K.V. Serum interleukin-2 concentrations in Guillain-Barre syndrome and chronic idiopathic demyelinating polyradiculoneuropathy: comparison with other neurological diseases of presumed immunopathogenesis. Ann Neurol 1991, 30:48-53.
76. Utsugisawa K., Sano M. [Interleukin-2 production by peripheral blood mononuclear cell from patients with myasthenia gravis-correlation with clinical severity]. Rinsho Shinkeigaku 1992, 32:474-478.
77. Link J., He B., Navikas V., Palasik W., Fredrikson S., Soderstrom M., et al. Transforming growth factor-beta 1 suppresses autoantigen-induced expression of pro-inflammatory cytokines but not of interleukin-10 in multiple sclerosis and myasthenia gravis. JNeuroimmunol 1995, 58:21-35.
78. Huang Y.M., Kivisakk P., Ozenci V., Pirskanen R., Link H. Increased levels of circulating acetylcholine receptor (AChR)-reactive IL-10-secreting cells are characteristic for myasthenia gravis (MG). Clin Exp Immunol 1999, 118:304-308.
79. Yi Q., Lefvert A.K. Idiotype- and anti-idiotype-reactive T lymphocytes in myasthenia gravis. Evidence for the involvement of different subpopulations of T helper lymphocytes. JImmunol 1994, 153:3353-3359.
80. Shimada K., Koh C.S., Yanagisawa N. [Detection of interleukin-6 in serum and cerebrospinal fluid of patients with neuroimmunological diseases]. Arerugi 1993, 42:934-940.
81. Link J., Fredrikson S., Soderstrom M., Olsson T., Hojeberg B., Ljungdahl A., et al. Organ-specific autoantigens induce transforming growth factor-beta mRNA expression in mononuclear cells in multiple sclerosis and myasthenia gravis. Ann Neurol 1994, 35:197-203.
82. Kim J.Y., Yang Y., Moon J.S., Lee E.Y., So S.H., Lee H.S., et al. Serum BAFF expression in patients with myasthenia gravis. JNeuroimmunol 2008, 199:151-154.
83. Ragheb S., Lisak R., Lewis R., Van Stavern G., Gonzales F., Simon K. Apotential role for B-cell activating factor in the pathogenesis of autoimmune myasthenia gravis. Arch Neurol 2008, 65:1358-1362.
84. Nakano S., Engel A.G. Myasthenia gravis: quantitative immunocytochemical analysis of inflammatory cells and detection of complement membrane attack complex at the end-plate in 30 patients. Neurology 1993, 43:1167-1172.
85. Yin W., Allman W., Ouyang S., Li Y., Li J., Christadoss P., et al. The increased expression of CD21 on AchR specified B cells in patients with myasthenia gravis. JNeuroimmunol 2013, 256:49-54.
86. Selcen D., Fukuda T., Shen X.M., Engel A.G. Are MuSK antibodies the primary cause of myasthenic symptoms?. Neurology 2004, 62:1945-1950.
87. Schluep M., Willcox N., Vincent A., Dhoot G.K., Newsom-Davis J. Acetylcholine receptors in human thymic myoid cells in situ: an immunohistological study. Ann Neurol 1987, 22:212-222.
88. Leite M.I., Jones M., Strobel P., Marx A., Gold R., Niks E., et al. Myasthenia gravis thymus: complement vulnerability of epithelial and myoid cells, complement attack on them, and correlations with autoantibody status. Am J Pathol 2007, 171:893-905.
89. Scadding G.K., Vincent A., Newsom-Davis J., Henry K. Acetylcholine receptor antibody synthesis by thymic lymphocytes: correlation with thymic histology. Neurology 1981, 31:935-943.
90. Guigou V., Emilie D., Berrih-Aknin S., Fumoux F., Fougereau M., Schiff C. Individual germinal centres of myasthenia gravis human thymuses contain polyclonal activated B cells that express all the Vh and Vk families. Clin Exp Immunol 1991, 83:262-266.
91. Meriggioli M.N., Sanders D.B. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol 2009, 8:475-490.
92. Emilie D., Crevon M.C., Cohen-Kaminsky S., Peuchmaur M., Devergne O., Berrih-Aknin S., et al. In situ production of interleukins in hyperplastic thymus from myasthenia gravis patients. Human Pathol 1991, 22:461-468.
93. Cohen-Kaminsky S., Delattre R.M., Devergne O., Klingel-Schmitt I., Emilie D., Galanaud P., et al. High IL-6 gene expression and production by cultured human thymic epithelial cells from patients with myasthenia gravis. Ann N Y Acad Sci 1993, 681:97-99.
94. Cohen-Kaminsky S., Devergne O., Delattre R.M., Klingel-Schmitt I., Emilie D., Galanaud P., et al. Interleukin-6 overproduction by cultured thymic epithelial cells from patients with myasthenia gravis is potentially involved in thymic hyperplasia. Eur Cytokine Netw 1993, 4:121-132.
95. Aime C., Cohen-Kaminsky S., Berrih-Aknin S. Invitro interleukin-1 (IL-1) production in thymic hyperplasia and thymoma from patients with myasthenia gravis. JClin Immunol 1991, 11:268-278.
96. Mandapathil M., Hilldorfer B., Szczepanski M.J., Czystowska M., Szajnik M., Ren J., et al. Generation and accumulation of immunosuppressive adenosine by human CD4+CD25highFOXP3+ regulatory T cells. JBiol Chem 2010, 285:7176-7186.
97. Loza M.J., Anderson A.S., O'Rourke K.S., Wood J., Khan I.U. T-cell specific defect in expression of the NTPDase CD39 as a biomarker for lupus. Cell Immunol 2011, 271:110-117.
98. Hain B., Jordan K., Deschauer M., Zierz S. Successful treatment of MuSK antibody-positive myasthenia gravis with rituximab. Muscle Nerve 2006, 33:575-580.
99. Thakre M., Inshasi J., Marashi M. Rituximab in refractory MuSK antibody myasthenia gravis. JNeurol 2007, 254:968-969.
100. Nowak R.J., Dicapua D.B., Zebardast N., Goldstein J.M. Response of patients with refractory myasthenia gravis to rituximab: a retrospective study. Ther Adv Neurol Disord 2011, 4:259-266.